AGIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AGIO is a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to invest. My view is positive because the stock has fresh earnings momentum, strong revenue growth, improving commercial traction from Aqvesme, and multiple regulatory catalysts ahead. The stock is not in a perfect technical setup, but for a long-term investor who is impatient and wants a direct answer, this is a buy now rather than a wait.
The price closed at 27.00, slightly above the 26.638 pivot and below resistance at 28.368. RSI_6 at 49.04 is neutral, while MACD histogram at -0.0681 is still below zero but contracting, which suggests bearish pressure is easing. However, the moving averages are still bearish with SMA_200 > SMA_20 > SMA_5, so the broader trend is not fully reversed yet. Short-term price action is mixed, but the stock is holding near support and has room to test 28.37 and 29.44 if momentum continues.
["Strong Q1 2026 earnings reaction, with the stock rising 11.2% after the report.", "Aqvesme sales jumped to $20.7M from $8.7M year over year, showing strong commercial growth.", "Management plans to file for accelerated FDA approval of mitapivat for sickle cell disease in Q2 2026.", "Upcoming Phase 2 tebapivat results expected in 2026 provide another pipeline catalyst.", "Hedge funds are buying aggressively, with buying up 297.63% over the last quarter.", "Congress trading was positive, with 1 purchase and 0 sales in the last 90 days.", "Analysts still mostly maintain Buy ratings despite some price target cuts, signaling continued fundamental support.", "News flow has been constructive and growth-focused rather than deteriorating."]
["The technical trend remains weak at the medium term, with SMA_200 > SMA_20 > SMA_5.", "MACD is still negative, indicating the stock has not yet confirmed a full trend reversal.", "Recent analyst price target reductions show some caution around regulatory risk and competition.", "Novo Nordisk's positive HIBISCUS data increases competitive pressure for mitapivat in sickle cell disease.", "Net income remains deeply negative at -$99.1M in Q1 2026, so the company is still loss-making."]
In Q1 2026, Agios delivered strong top-line growth, with revenue up 137.75% year over year to $20.75M. Aqvesme sales were the key driver, rising to $20.7M from $8.7M in the prior-year quarter. Gross margin improved to 93.64%, which is very strong. On the negative side, net income was still -$99.11M and EPS was -$1.69, so profitability has not yet turned positive. Latest quarter season: Q1 2026. Overall, the financial picture is improving quickly on revenue and product traction, but still not profitable.
Recent analyst sentiment is mixed but still constructive. Truist lowered its target to $36 and kept Buy. BofA cut its target to $41 and kept Buy. H.C. Wainwright lowered to $50 and kept Buy, while also highlighting higher competitive risk. JPMorgan and Goldman both raised targets to $36 and $32 respectively, but kept Neutral. Citi had earlier raised to $46 with a Buy rating and an upside catalyst watch. Overall, Wall Street remains split between Buy and Neutral, with the main pro view being regulatory upside and commercial momentum, and the main con view being competition and regulatory risk. The target trend is slightly downward recently, but not bearish enough to override the underlying positive thesis.
